JP2016540045A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540045A5 JP2016540045A5 JP2016554526A JP2016554526A JP2016540045A5 JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5 JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5
- Authority
- JP
- Japan
- Prior art keywords
- benzoic acid
- ethynyl
- phenylethynyl
- pyrrol
- indol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C=Cc1nccc(*)c1I* Chemical compound *C=Cc1nccc(*)c1I* 0.000 description 10
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904555P | 2013-11-15 | 2013-11-15 | |
| US61/904,555 | 2013-11-15 | ||
| PCT/US2014/065765 WO2015073864A1 (en) | 2013-11-15 | 2014-11-14 | Ebna1 inhibitors and their method of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129107A Division JP2020196723A (ja) | 2013-11-15 | 2020-07-30 | Ｅｂｎａ１阻害剤およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540045A JP2016540045A (ja) | 2016-12-22 |
| JP2016540045A5 true JP2016540045A5 (enExample) | 2017-11-30 |
| JP6744218B2 JP6744218B2 (ja) | 2020-08-19 |
Family
ID=53058091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554526A Active JP6744218B2 (ja) | 2013-11-15 | 2014-11-14 | Ｅｂｎａ１阻害剤およびそれらの使用方法 |
| JP2020129107A Withdrawn JP2020196723A (ja) | 2013-11-15 | 2020-07-30 | Ｅｂｎａ１阻害剤およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020129107A Withdrawn JP2020196723A (ja) | 2013-11-15 | 2020-07-30 | Ｅｂｎａ１阻害剤およびそれらの使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9856214B2 (enExample) |
| EP (1) | EP3068758B1 (enExample) |
| JP (2) | JP6744218B2 (enExample) |
| KR (1) | KR20160110357A (enExample) |
| CN (1) | CN105934425B (enExample) |
| AU (2) | AU2014348422B2 (enExample) |
| BR (1) | BR112016011079A2 (enExample) |
| CA (1) | CA2930584A1 (enExample) |
| MX (1) | MX2016006325A (enExample) |
| WO (1) | WO2015073864A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016006325A (es) | 2013-11-15 | 2016-12-02 | Wistar Inst | Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso. |
| EP3294705B1 (en) | 2015-05-14 | 2021-07-21 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and methods using same |
| WO2017100819A1 (en) * | 2015-12-14 | 2017-06-22 | The Australian National University | Modular syntheses of discoipyrrole type alkaloids and analogues |
| US11046731B2 (en) * | 2018-01-18 | 2021-06-29 | Hong Kong Baptist University | Zinc-binder based EBNA1-specific compounds |
| AU2019263176B2 (en) * | 2018-04-30 | 2025-02-27 | The Trustees Of Indiana University | Compounds for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease |
| WO2019222470A1 (en) | 2018-05-17 | 2019-11-21 | The Wistar Institute | Ebna1 inhibitor crystalline forms, and methods of preparing and using same |
| CN113754541B (zh) * | 2020-06-02 | 2025-01-03 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
| CN115141176B (zh) * | 2021-03-31 | 2023-08-22 | 药雅科技(上海)有限公司 | 炔代吲哚类fgfr抑制剂及其制备方法和用途 |
| CN116135850A (zh) * | 2021-11-16 | 2023-05-19 | 深圳湾实验室 | 抗鼻咽癌的小分子抑制剂、化合物的制备方法及其应用 |
| WO2024050408A1 (en) * | 2022-08-30 | 2024-03-07 | The Wistar Institute Of Anatomy And Biology | Development of a novel ebna-1 degrader targeting through mdm2 |
| CN117586230B (zh) * | 2023-10-20 | 2024-09-24 | 南方医科大学深圳医院 | 降解ebna1的protac化合物及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| HU190007B (en) | 1982-05-06 | 1986-08-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing new aromatic prostacylin analogues |
| DE3936297A1 (de) | 1989-11-01 | 1991-05-02 | Bayer Ag | Verfahren zur herstellung von symmetrischen diarylacetylenen |
| DE4039448A1 (de) | 1990-12-11 | 1992-06-17 | Rhein Chemie Rheinau Gmbh | Polyurethan-katalysatoren |
| US5356919A (en) * | 1991-05-30 | 1994-10-18 | G. D. Searle & Co. | Leukotriene B4 synthesis inhibitors |
| US6166028A (en) * | 1998-12-09 | 2000-12-26 | American Home Products Corporation | Diaminopuridine-containing thiourea inhibitors of herpes viruses |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| OA12274A (en) | 2000-05-22 | 2006-05-09 | Aventis Pharma Inc | Arylmethylamine derivatives for use as tryptase inhibitors. |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| EP1568692B1 (en) | 2000-05-31 | 2010-09-15 | Santen Pharmaceutical Co., Ltd. | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| US20040044041A1 (en) * | 2002-08-06 | 2004-03-04 | Kuduk Scott D. | 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives |
| US7361743B2 (en) | 2004-02-11 | 2008-04-22 | Pfizer Inc | Lincomycin derivatives possessing antibacterial activity |
| CN1288117C (zh) * | 2004-04-02 | 2006-12-06 | 中国科学院上海有机化学研究所 | 端基炔烃和芳基卤化物的偶联反应 |
| NZ551974A (en) * | 2004-07-02 | 2010-01-29 | Inst Medical W & E Hall | Alpha-helical minetics |
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| EP1776338A1 (en) * | 2004-08-05 | 2007-04-25 | F. Hoffmann-Roche AG | Indole, indazole or indoline derivatives |
| MX2007014085A (es) | 2005-05-12 | 2008-02-07 | Wyeth Corp | Pirrolobenzodiazepinas y derivados de carboxamida heterociclica como antagonistas de receptor de hormona estimulante del foliculo. |
| DK2395004T3 (en) * | 2005-06-22 | 2016-03-21 | Plexxikon Inc | Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors |
| WO2007002587A2 (en) | 2005-06-24 | 2007-01-04 | The Brigham And Women's Hospital, Inc. | Inhibitors of epstein barr virus nuclear antigen 1 |
| WO2007023242A1 (en) * | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
| EP2049493B1 (en) * | 2006-07-31 | 2012-03-21 | Cadila Healthcare Limited | Compounds suitable as modulators of hdl |
| US7956216B2 (en) * | 2006-12-21 | 2011-06-07 | The Walter And Eliza Hall Institute Of Medical Research | Alpha-helical mimetics |
| WO2010048332A2 (en) | 2008-10-22 | 2010-04-29 | Acucela, Inc. | Compounds for treating ophthalmic diseases and disorders |
| WO2010092043A1 (en) | 2009-02-12 | 2010-08-19 | Merck Serono S.A. | Phenoxy acetic acid derivatives |
| WO2010100475A1 (en) * | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
| US8927576B2 (en) * | 2009-04-06 | 2015-01-06 | PTC Therpeutics, Inc. | HCV inhibitor and therapeutic agent combinations |
| WO2010124047A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5) |
| MX2011011757A (es) * | 2009-05-04 | 2012-01-25 | Prometic Biosciences Inc | Compuestos aromaticos substituidos y usos farmaceuticos. |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011082098A1 (en) | 2009-12-30 | 2011-07-07 | The Rockefeller University | Lysine and arginine methyltransferase inhibitors for treating cancer |
| US8735384B2 (en) * | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| AU2012208388C1 (en) * | 2011-01-21 | 2017-04-27 | Sun Pharma Advanced Research Company Ltd | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| US9309212B2 (en) | 2011-05-24 | 2016-04-12 | The Wistar Institute | Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1 |
| EP2968276A4 (en) * | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| MX2016006325A (es) * | 2013-11-15 | 2016-12-02 | Wistar Inst | Inhibidores del antígeno nuclear 1 de epstein-barr, y su método de uso. |
-
2014
- 2014-11-14 MX MX2016006325A patent/MX2016006325A/es unknown
- 2014-11-14 EP EP14861658.4A patent/EP3068758B1/en active Active
- 2014-11-14 CN CN201480073152.2A patent/CN105934425B/zh active Active
- 2014-11-14 CA CA2930584A patent/CA2930584A1/en not_active Abandoned
- 2014-11-14 US US15/036,211 patent/US9856214B2/en active Active
- 2014-11-14 WO PCT/US2014/065765 patent/WO2015073864A1/en not_active Ceased
- 2014-11-14 JP JP2016554526A patent/JP6744218B2/ja active Active
- 2014-11-14 BR BR112016011079A patent/BR112016011079A2/pt not_active Application Discontinuation
- 2014-11-14 AU AU2014348422A patent/AU2014348422B2/en active Active
- 2014-11-14 KR KR1020167015855A patent/KR20160110357A/ko not_active Ceased
-
2017
- 2017-11-16 US US15/814,600 patent/US10421718B2/en active Active
-
2019
- 2019-04-24 AU AU2019202905A patent/AU2019202905A1/en not_active Abandoned
- 2019-07-23 US US16/519,590 patent/US11242317B2/en active Active
-
2020
- 2020-07-30 JP JP2020129107A patent/JP2020196723A/ja not_active Withdrawn
-
2021
- 2021-12-22 US US17/558,877 patent/US12258314B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6203781B2 (ja) | Ｃ−ｆｍｓおよび／またはｃ−ｋｉｔ活性を調節する化合物およびその用途 | |
| JP2012525431A5 (enExample) | ||
| TWI617552B (zh) | 用於激酶調節及其適應症之化合物及方法 | |
| AU2005216904B2 (en) | Modulation of inflammatory and metastatic processes | |
| JP6318156B2 (ja) | キナーゼをモジュレートするための化合物および方法、ならびにその指標 | |
| JP5808793B2 (ja) | キナーゼ調節のための化合物および方法、ならびにそれらの適応症 | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| JP4462930B2 (ja) | ピリミジン化合物及びその医薬組成物 | |
| RU2013123274A (ru) | Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы | |
| JP6523311B2 (ja) | 局所投与用薬学的組成物 | |
| JP2017518961A (ja) | 免疫調節剤として有用な化合物 | |
| JP2012528178A5 (enExample) | ||
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| TW201010977A (en) | Amide compound | |
| RU2010137114A (ru) | Амидные производные как позитивные аллостерические модуляторы и способы их применения | |
| JP2014527529A5 (enExample) | ||
| RU2012155712A (ru) | Новые производные пиримидина | |
| AU2019202905A1 (en) | EBNA1 inhibitors and their method of use | |
| ATE455756T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| JP3332232B2 (ja) | ピペリジル―置換されたインドール | |
| JP2018535930A (ja) | ３−ヒドロキシ−キナゾリン−２，４−ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用 | |
| KR20230118593A (ko) | Alk-5 억제제 및 이의 용도 | |
| RU2015150614A (ru) | Новые 3, 4-дигидро-2н-изохинолин-1-оны и 2, 3-дигидро-изоиндол-1-оны | |
| HRP20191532T1 (hr) | Imidazolilni substituirani indolski derivativi koji povezuju 5-ht7 serotonin receptor i njihovi farmaceutski pripravci | |
| MY147474A (en) | 1-[(4-[benzoyl(methyl)amino]-3-(phenyl)butyl]azetidine derivatives for the treatment of gastrointestinal disorders 1 |